80-Gene Molecular Subtyping Assay
BluePrint is a breast cancer genomic test that identifies your tumor’s molecular subtypes and may help guide a physician when making treatment recommendations.
Everybody’s breast cancer is different and may respond differently to treatment. Your physician uses diagnostic tests to identify the specific characteristics of your cancer to help determine what treatment would be best for you. These characteristics are known as your cancer’s subtype.
Traditionally, common subtype tests include the IHC (Immunohistochemisty) test or the FISH (Fluorescence in situ hybridization) test. These tests identify a tumor’s subtype by looking at cell surface characteristics. The results will tell your physician whether your tumor is estrogen receptor positive or negative (ER +/-), progesterone positive or negative (PR +/-), and human epidermal growth factor receptor 2 positive or negative (HER2 +/-).
Instead of looking at cell surface characteristics, technology today allows physicians to go a step further to identify “gene expression”. This allows your physician to look at genes at a more functional level to see what is driving your tumor’s behavior. This is called “molecular subtyping.”
BluePrint analyzes 80 different genes to classify your tumor into three different functional molecular subtypes: Luminal-type, HER2-type and Basal-type, each with marked differences in long-term outcome and response to neoadjuvant chemotherapy.1 According to a study in Cancer Research, the BluePrint molecular subtyping reclassifies up to 25% of breast cancers from traditional diagnostic tests like IFC and FISH.2
 Glück S. et al. Breast Cancer Res Treat. (June 2013) 139(3):759-767
 Cristofanilli M. et al. Cancer Res. 2012;72(24 Suppl):Abstract nr P3-05-01.